Evidence map›Paper›PMID 28670130›Full record

ArticleTherapeutics and clinical risk management2017

Four novel

Masoumeh Dehghan Manshadi, Behnam Kamalidehghan, Omid Aryani, Elham Khalili, Sepideh Dadgar, Mahdi Tondar, Fatemeh Ahmadipour, Goh Yong Meng, Massoud Houshmand

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Therapeutics and clinical risk management, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Novel advanced patient-derivedFrontiers in neurology
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 3 countries.

Masoumeh Dehghan ManshadiDepartment of Medical Genetics, Special Medical Center, Tehran, Iran.
Behnam KamalidehghanMedical Genetics Department, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Omid AryaniDepartment of Medical Genetics, Special Medical Center, Tehran, Iran.
Elham KhaliliDepartment of Medical Genetics, Special Medical Center, Tehran, Iran.
Sepideh DadgarDepartment of Medical Genetics, Special Medical Center, Tehran, Iran.
Mahdi TondarDepartment of Biochemistry and Molecular & Cellular Biology, School of Medicine, Georgetown University, Washington, DC, USA.
Fatemeh AhmadipourDepartment of Pharmacy, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.
Goh Yong MengDepartment of Veterinary Preclinical Sciences, Faculty of Veterinary Medicine, Universiti Putra Malaysia, Selangor, Malaysia.
Massoud HoushmandDepartment of Medical Genetics, Special Medical Center, Tehran, Iran.
National Institute of Genetic Engineering and Biotechnology · IRGeorgetown University · USUniversiti Putra Malaysia · MYUniversity of Malaya · MY

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Metachromatic leukodystrophy (MLD) disorder is a rare lysosomal storage disorder that leads to severe neurological symptoms and an early death. MLD occurs due to the deficiency of enzyme arylsulfatase A (ARSA) in leukocytes, and patients with MLD excrete sulfatide in their urine. In this study, the

Indexed as

behavioral disturbancesdemyelinatinggait abnormality and impairmentmetachromatic leukodystrophy (MLD)psychomotor regression

Identifiers

PMID28670130
PMCPMC5482404
OpenAlexW2626324886

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.